Literature DB >> 25644248

Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.

M Abd-Alazeez1, N Ramachandran2, N Dikaios3, H U Ahmed4, M Emberton4, A Kirkham2, M Arya5, S Taylor3, S Halligan3, S Punwani3.   

Abstract

BACKGROUND: Multiparametric magnetic resonance imaging (mp-MRI) is increasingly advocated for prostate cancer detection. There are limited reports of its use in the setting of radiorecurrent disease. Our aim was to assess mp-MRI for detection of radiorecurrent prostate cancer and examine the added value of its functional sequences.
METHODS: Thirty-seven men with mean age of 69.7 (interquartile range, 66-74) with biochemical failure after external beam radiotherapy underwent mp-MRI (T2-weighted, high b-value, multi-b-value apparent diffusion coefficient (ADC) and dynamic contrast-enhanced (DCE) imaging); then transperineal systematic template prostate mapping (TPM) biopsy. Using a locked sequential read paradigm (with the sequence order above), two experienced radiologists independently reported mp-MRI studies using score 1-5. Radiologist scores were matched with TPM histopathology at the hemigland level (n=74). Accuracy statistics were derived for each reader. Interobserver agreement was evaluated using kappa statistics.
RESULTS: Receiver-operator characteristic area under curve (AUC) for readers 1 and 2 increased from 0.67 (95% confidence interval (CI), 0.55-0.80) to 0.80 (95% CI, 0.69-0.91) and from 0.67 (95% CI, 0.55-0.80) to 0.84 (95% CI, 0.76-0.93), respectively, between T2-weighted imaging alone and full mp-MRI reads. Addition of ADC maps and DCE imaging to the examination did not significantly improve AUC for either reader (P=0.08 and 0.47 after adding ADC, P=0.90 and 0.27 after adding DCE imaging) compared with T2+high b-value review. Inter-reader agreement increased from k=0.39 to k=0.65 between T2 and full mp-MRI review.
CONCLUSIONS: mp-MRI can detect radiorecurrent prostate cancer. The optimal examination included T2-weighted imaging and high b-value DWI; adding ADC maps and DCE imaging did not significantly improve the diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25644248     DOI: 10.1038/pcan.2014.55

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  33 in total

1.  The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings.

Authors:  Taylan Kara; Deniz Akata; Fadıl Akyol; Muşturay Karçaaltıncaba; Mustafa Özmen
Journal:  Diagn Interv Radiol       Date:  2010-08-12       Impact factor: 2.630

2.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.

Authors:  Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz
Journal:  J Magn Reson Imaging       Date:  2012-04-25       Impact factor: 4.813

3.  Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer.

Authors:  Byung Kwan Park; Bohyun Kim; Chan Kyo Kim; Hyun Moo Lee; Ghee Young Kwon
Journal:  J Comput Assist Tomogr       Date:  2007 Jul-Aug       Impact factor: 1.826

4.  Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience.

Authors:  Chan Kyo Kim; Byung Kwan Park; Won Park; Sam Soo Kim
Journal:  Abdom Imaging       Date:  2009-01-07

5.  Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

6.  Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results.

Authors:  Oguz Akin; David H Gultekin; Hebert Alberto Vargas; Junting Zheng; Chaya Moskowitz; Xin Pei; Dahlia Sperling; Lawrence H Schwartz; Hedvig Hricak; Michael J Zelefsky
Journal:  Eur Radiol       Date:  2011-05-01       Impact factor: 5.315

7.  Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.

Authors:  Tom Pickles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-10       Impact factor: 7.038

8.  Endorectal MRI after radiation therapy: questioning the sextant analysis.

Authors:  Shilpa R Kumbhani; Fergus V Coakley; Charles E McCulloch; Z Jane Wang; John Kurhanewicz; Mack Roach; Antonio C Westphalen
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

9.  T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy.

Authors:  Antonio C Westphalen; John Kurhanewicz; Rui M G Cunha; I-Chow Hsu; John Kornak; Shoujun Zhao; Fergus V Coakley
Journal:  Int Braz J Urol       Date:  2009 Mar-Apr       Impact factor: 1.541

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  19 in total

1.  Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy.

Authors:  Luca F Valle; Matthew D Greer; Joanna H Shih; Tristan Barrett; Yan Mee Law; Andrew B Rosenkrantz; Haytham Shebel; Akhil Muthigi; Daniel Su; Maria J Merino; Bradford J Wood; Peter A Pinto; Andra V Krauze; Aradhana Kaushal; Peter L Choyke; Barış Türkbey; Deborah E Citrin
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

2.  The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.

Authors:  L C McLoughlin; S Inder; D Moran; C O'Rourke; R P Manecksha; T H Lynch
Journal:  Ir J Med Sci       Date:  2017-06-13       Impact factor: 1.568

3.  Prostate cancer: Post-treatment imaging-a desperate need for solid evidence.

Authors:  Olivier Rouvière
Journal:  Nat Rev Urol       Date:  2015-04-28       Impact factor: 14.432

Review 4.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

5.  Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI.

Authors:  Liza Lindenberg; Esther Mena; Baris Turkbey; Joanna H Shih; Sarah E Reese; Stephanie A Harmon; Ilhan Lim; Frank Lin; Anita Ton; Yolanda L McKinney; Philip Eclarinal; Deborah E Citrin; William Dahut; Ravi Madan; Bradford J Wood; Venkatesh Krishnasamy; Richard Chang; Elliot Levy; Peter Pinto; Janet F Eary; Peter L Choyke
Journal:  Radiology       Date:  2020-07-07       Impact factor: 11.105

Review 6.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06

7.  Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?

Authors:  Raïssa Lotte; Alexandre Lafourcade; Pierre Mozer; Pierre Conort; Eric Barret; Eva Comperat; Malek Ezziane; Paul-Hugo Jouve de Guibert; Sebastian Tavolaro; Lisa Belin; Franck Boudghene; Olivier Lucidarme; Raphaële Renard-Penna
Journal:  Eur Radiol       Date:  2018-04-09       Impact factor: 5.315

8.  Positive prostate biopsy following radiotherapy can predict metastasis-free survival in localized prostate cancer.

Authors:  A Zapatero; M Adrados; L Torres; M S Talaya; A Cruz Conde; C Martin de Vidales; L Vega Piris; C Olivier; M T Murillo
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

9.  Helical tomotherapy re-irradiation for patients affected by local radiorecurrent prostate cancer.

Authors:  Cristina Mariucci; Gianluca Ingrosso; Vittorio Bini; Simonetta Saldi; Marco Lupattelli; Alessandro Frattegiani; Elisabetta Perrucci; Isabella Palumbo; Lorenzo Falcinelli; Giuseppe Centofanti; Rita Bellavita; Cynthia Aristei
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-22

10.  Detection and staging of radio-recurrent prostate cancer using multiparametric MRI.

Authors:  Jie-Ying Kowa; Neil Soneji; S Aslam Sohaib; Erik Mayer; Stephen Hazell; Nicholas Butterfield; Joshua Shur; Derfel Ap Dafydd
Journal:  Br J Radiol       Date:  2021-02-15       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.